Roche participated in the Agilent Technologies-led round, which will fund the launch of Stanford spinout Purigen's isotachophoresis-based DNA and RNA sample preparation platform.
Purigen Biosystems, a US-based laboratory technology spinout of Stanford University, has raised $26.4m in a series B round led by diagnostics services provider Agilent Technologies.
Roche Venture Fund, the corporate venturing unit of pharmaceutical firm Roche, also took part in the round, as did investment firm Cota Capital and venture capital firm 5AM Ventures.
Purigen is developing a platform that allows users to purify DNA and RNA from biological samples, including mammalian cells, fresh or formalin-fixed paraffin-embedded tissues,…
